Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.61 |
| ▸ | GRM5 | P41594 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | P4HB | P07237 | 2/20 | 0.46 |
| ▸ | CLK1 | P49759 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.46 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.45 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.45 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.45 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.45 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30239069 | 1.00 | GSK3B (0.61) | GSK3BGRM5ALDH1A1MAPTMEN1 | |
| SCHEMBL4060948 | 0.89 | KAT6A (0.53) | GSK3BDYRK1B | |
| SCHEMBL6578442 | 0.87 | GSK3B (0.85) | GSK3BGRM5ALDH1A1MAPTMEN1 | |
| SCHEMBL22801100 | 0.85 | MEN1 (0.55) | ALDH1A1MAPTMEN1KMT2APDK1 | |
| SCHEMBL8615592 | 0.83 | ACACB (0.57) | GRM5ALDH1A1MEN1KMT2A | |
| SCHEMBL11808658 | 0.83 | GSK3B (0.55) | GSK3BGRM5ALDH1A1MAPTP4HB | |
| SCHEMBL7452826 | 0.82 | GSK3B (0.54) | GSK3BGRM5P4HBCLK1DYRK1A | |
| SCHEMBL7452810 | 0.82 | GSK3B (0.54) | GSK3BGRM5P4HBCLK1DYRK1A | |
| SCHEMBL7452824 | 0.82 | GSK3B (0.54) | GSK3BGRM5P4HBCLK1DYRK1A | |
| SCHEMBL2164429 | 0.82 | GSK3B (0.62) | GSK3BGRM5ALDH1A1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250075147-A1 | FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NEW FLAVOR AND FRAGRANCE INGREDIENTS | OSMO LABS, PBC | 2025-03-06 | — | — | US | claimed |
| CN-115925527-B | Method for preparing alpha-diaryl methyl substituted ketone compound | 湖南理工学院 | 2024-02-09 | — | — | CN | claimed |
| CN-115925527-A | Method for preparing alpha-diaryl methyl substituted ketone compound | 湖南理工学院 | 2023-04-07 | — | — | CN | claimed |
| EP-2529388-B1 | FRAGMENTATION REAGENTS FOR MASS SPECTROMETRY | MICROMASS LTD (GB) | 2019-10-23 | — | — | EP | claimed |
| CN-102267915-B | Method for reducing aromatic nitriles | UNIV ZHEJIANG | 2013-11-20 | — | — | CN | claimed |
| CN-102276377-B | Method for preparing benzylamine | UNIV ZHEJIANG | 2013-08-07 | — | — | CN | claimed |
| CN-102276377-A | Method for preparing benzylamine | — | 2011-12-14 | — | — | CN | claimed |
| CN-102267915-A | Method for reducing aromatic nitriles | — | 2011-12-07 | — | — | CN | claimed |
| US-7951827-B2 | Synthesis and antiprotozoal activity of dicationic 3,5-diphenylisoxazoles | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2011-05-31 | — | — | US | claimed |
| US-7368463-B2 | Substituted 4-amino-1-benzylpiperidine compounds | THERAVANCE, INC. (US) | 2008-05-06 | — | — | US | claimed |
| EP-1644356-A1 | SUBSTITUTED 4-AMINO-1-BENZYLPIPERIDINE COMPOUNDS | Theravance, Inc. (US) | 2006-04-12 | — | — | EP | claimed |
| EP-1556372-A2 | SUBSTITUTED 4-AMINO-1-(PYRIDYLMETHYL) PIPERIDINE AS MUSCARINIC RECEPTOR ANTAGONISTS | Theravance, Inc. (US) | 2005-07-27 | — | — | EP | claimed |
| US-20050026954-A1 | Muscarinic receptor antagonists; overactive bladder, irritable bowel syndrome, chronic obstructive pulmonary disease, and asthma | THERAVANCE BIOPHARMA R&D IP, LLC | 2005-02-03 | — | — | US | claimed |
| WO-2005007645-A1 | SUBSTITUTED 4-AMINO-1-BENZYLPIPERIDINE COMPOUNDS | THERAVANCE, INC. (US) | 2005-01-27 | — | — | WO | claimed |
| US-20040122014-A1 | Muscarinic M2 receptor antagonists; such as 4-{N-[7-(3-1-carbamoyl-1,1-diphenylmethyl)pyrrolidin-1-yl)hept-1-yl]-N-(isopropyl)amino}-1-(4-methoxypyrid-3-ylmethyl)piperidine; reduced blurred vision, constipation and dry mouth side effects | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-06-24 | — | — | US | claimed |
| WO-2004041806-A2 | SUBSTITUTED 4-AMINO-1-(PYRIDYLMETHYL) PIPERIDINE AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2004-05-21 | — | — | WO | claimed |
| US-6336963-B1 | INK COMPOSITION COMPRISING INK VEHICLE COMPRISING FIRST NITRILE COMPOUND HAVING FIRST VISCOSITY AT MELT TEMPERATURE, VISCOSITY MODIFIER COMPRISING SECOND NITRILE COMPOUND HAVING LOWER VISCOSITY AT MELT TEMPERATURE, COLORANT | XEROX CORPORATION | 2002-01-08 | — | — | US | claimed |
| EP-0043480-B1 | PROCESS FOR FORMING METALLIC IMAGES | Hitachi, Ltd. (JP) | 1985-04-03 | — | — | EP | claimed |
| US-4347304-A | PHOTOSENSITIZATION WITH DISILANES OR ORGANIC COMPOUNDS HAVING COUPLED GERMANIUM OR TIN MOLECULES; PHOTORESISTS; POSITIVES; PLATING | HITACHI, LTD. (JP) | 1982-08-31 | — | — | US | claimed |
| EP-0043480-A2 | Process for forming metallic images | Hitachi, Ltd. (JP) | 1982-01-13 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122014-A1 | Muscarinic M2 receptor antagonists; such as 4-{N-[7-(3-1-carbamoyl-1,1-diphenylmethyl)pyrrolidin-1-yl)hept-1-yl]-N-(isopropyl)amino}-1-(4-methoxypyrid-3-ylmethyl)piperidine; reduced blurred vision, constipation and dry mouth side effects | CHRM2, CHRM1, CHRM3 | GSK3B 4644/4885GRM5 127/4885ALDH1A1 1429/4885 |
| US-20050026954-A1 | Muscarinic receptor antagonists; overactive bladder, irritable bowel syndrome, chronic obstructive pulmonary disease, and asthma | CHRM5, CHRM3, CHRM1 | GSK3B 3007/4885GRM5 146/4885ALDH1A1 1154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.